Appendix 2: Comparison of State Pharmaceutical Company Payment Disclosure Laws

		DC¹	ME ²	MN ³	VT⁴	WV ⁵					
	Disclosure Requirements										
	Device and biologic makers	No	No	No	No	No					
	Itemized report of each payment	Yes	Yes	No	Yes	No					
	Single entry per practitioner	No	No	Yes	No	No					
	Summary data only ⁶	No	No	No	No	Yes					
	Name of reporter	Yes*	Yes*	No	Yes	Yes*					
	Name of recipient	Yes	Yes	Yes	Yes	No					
	Type of recipient/credentials	Yes*	Yes*	Yes*	Yes*	No					
	License number	No	No	No	No	No					
	Location/address	No	No	Yes*	Yes*	No					
	Affiliated facility	No	No	No	Yes*	No					
	Date of payment	Yes*	Yes*	No	Yes*	No					
\sim	Amount	Yes	Yes	Yes	Yes	No					
\geq	Form of payment	Yes	Yes	Yes	Yes	No					
<u>7</u>	Purpose of payment	Yes	Yes	No	Yes	No					
×	Explicitly Included in Disclosure Requirement										
Ž	Educational programs/materials	Yes	Yes	Yes ⁷	"any gift, fee,						
ompany Disclosures to Agency	Food/entertainment/payments	Yes	Yes	N/A**	payment, subsidy, or	"gifts, grants,					
	Travel	Yes	Yes	N/A**	other economic	or payments of any kind"					
	Product samples (not intended as free for patients)	Yes	Yes	N/A**	benefit provided in connection with	which are "provided directly or indirectly"*					
	Honoraria/consulting fees	Yes*	Yes*	Yes	marketing activities"						
. <u>0)</u>	Explicitly Exempted from Disclosure Requirement										
	Payments less than	\$25	\$25	\$100 ⁸	\$25	\$100*					
	Clinical trials/research	Yes	Yes	No	Yes	Yes					
ī	Free samples for patients	Yes	Yes	Yes	Yes	Yes					
	Medical conferences ⁹	Yes	Yes	No	Yes	Yes					
\sim	Continuing medical education	No	No	No	Yes	No					
	Drug rebates/discounts	No	No	N/A**	Yes	No					
┕		Additi	<u>onal Feature</u>	S							
0	Submission via internet	No	Yes	No	Yes	No					
ŏ	Unit of enforcement	Civil action by Corp Counsel; \$1,000 fine for each false submission or omission	Civil action by AG; \$1,000 fine for failure to report	Disciplinary proceeding initiated by Board of Pharmacy; potential fine up to \$10,000 or loss of license	Civil action by AG; \$10,000 fine per violation	None provided by statute					
	Implementing agency	DoH	DHHS	Board of Pharmacy	AG	Pharm. Cost Management Council					
	Annual reporting fee	\$2,500	\$1,000	None	None	None					

Appendix 2: Comparison of State Pharmaceutical Company Payment Disclosure Laws

		DC¹	ME ²	MN ³	VT⁴	WV ⁵
Public Access to Disclosed Information	Disclosures explicitly made public record	No	No	Yes	No	No
Public to Disc Inforn	Disclosures explicitly exempted from open records act	Yes	Yes	No	No	Yes
	Report required	Yes	Yes	No	Yes	Yes
	Frequency	Annually	Annually	N/A	Annually	Annually
Agency Reports to Legislature	Report contents	Aggregate expenses (annually); analysis of effects on health care and recommend- ations (biannually)	Aggregate expenses (annually); analysis of effects on health care and recommend- ations (biannually)	N/A	Summary and aggregate of disclosed info	Aggregate data
Age	Report to	DC Council and Corp. Council	Leg. & AG	N/A	Leg. & Gov.	Leg. Committee
	Easily accessible on the internet	Reporting not yet begun	Reporting not yet begun	N/A	Yes	Reporting not yet begun

^{*} Indicates that requirement is not specified in state statute but is required by state agency.

^{**} These payments are banned under MN law.

¹ D.C. Code Ann. § 48-833.

² Me. Rev. Stat. Ann. Tit. 22, § 2698-A.

³ Minn. Stat. Ann. § 151.47.

⁴ Vt. Stat. Ann. Tit. 33, § 2005.

⁵ W. Va. Code Ann. § 5A-3C-13.

⁶ WV requires companies to indicate total number of prescribers who have received an aggregate amount in payments within specific dollar ranges.

⁷ MN only permits pharmaceutical companies to make payments directly to sponsors of bona fide medical education programs, and not to the practitioners themselves.

⁸ MN places a \$50 total yearly limit on all payments to practitioners, with exceptions for educational programs, honoraria, and consulting fees. Minn. Stat. Ann. § 151.461. All expenses excepted from the payment ban that total more than \$100 to a particular practitioner in one year must be reported.

⁹ DC, ME, VT, and WV permit pharmaceutical companies to exempt from reporting scholarships for conferences and seminars only if the association sponsoring the event chooses the recipient of the scholarship. WV and VT requires disclosure unless the recipient is a medical student, resident or fellow.